Scholar Rock Holding Pre-Tax Profit Margin 2017-2021 | SRRK

Scholar Rock Holding pre-tax profit margin from 2017 to 2021. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Scholar Rock Holding Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2021-09-30 $0.02B $-0.12B -688.89%
2021-06-30 $0.02B $-0.11B -687.50%
2021-03-31 $0.02B $-0.10B -653.33%
2020-12-31 $0.02B $-0.09B -580.00%
2020-09-30 $0.02B $-0.07B -360.00%
2020-06-30 $0.02B $-0.06B -290.91%
2020-03-31 $0.02B $-0.06B -252.17%
2019-12-31 $0.02B $-0.05B -247.62%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.572B $0.015B
Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88